Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 4/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10577006 | 0.98 | PPARA (0.52) | PPARACA1CA2CA12CA7 | |
| SCHEMBL10570553 | 0.94 | CA1 (0.52) | PPARACA1CA2CA12CA7 | |
| SCHEMBL15367310 | 0.86 | PPARA (0.49) | PPARACA1CA2CA12CA7 | |
| SCHEMBL195896 | 0.82 | GRIA1 (0.30) | — | |
| SCHEMBL11794520 | 0.78 | APP (0.35) | — | |
| SCHEMBL694651 | 0.78 | PPARA (0.60) | PPARACA1CA2CA12CA7 | |
| SCHEMBL1703654 | 0.76 | PPARA (0.64) | PPARACA1CA2CA12CA7 | |
| SCHEMBL19687777 | 0.76 | — | — | |
| SCHEMBL7691833 | 0.76 | PPARA (0.64) | PPARACA1CA2CA12CA7 | |
| SCHEMBL860710 | 0.75 | PPARA (0.52) | PPARACA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | claimed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | claimed |
| EP-2649091-B1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING NL KANKER INST (NL) | 2014-10-01 | — | — | EP | claimed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20140004137-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING SANQUIN BLOEDVOORZIENING (NL) | 2014-01-02 | — | — | US | claimed |
| EP-1907403-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | claimed |
| EP-2649091-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | Stichting Het Nederlands Kanker Instituut (NL) | 2013-10-16 | — | — | EP | claimed |
| WO-2012076708-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2012-06-14 | — | — | WO | claimed |
| WO-2012076059-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2012-06-14 | — | — | WO | claimed |
| WO-2007011658-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2007009109-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | claimed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1503990-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | Transmit Gesellschaft für Technologietransfer mbH (DE) | 2005-02-09 | — | — | EP | claimed |
| WO-2004056457-A2 | METHOD FOR SEPARATING POLYMER SYSTEMS AND PORE-FREE POLYMER FILMS USED IN SAID METHOD | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2004-07-08 | — | — | WO | claimed |
| EP-1049691-B1 | SUBSTITUTED 5-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL) CYCLOPENTENOPYRIDINE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | claimed |
| WO-2003095429-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | TransMIT Gesellschaft für Technologietransfer mbH (DE) | 2003-11-20 | — | — | WO | claimed |
| EP-0760658-B1 | COMPOUNDS FOR INHIBITING OSTEOCLAST-MEDIATED BONE RESORPTION | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004137-A1 | IMMUNE RESTRICTED PEPTIDES WITH INCREASED EFFICACY | TAP2, HLA-DRB1, HLA-C | PPARA 900/4885CA1 822/4885CA2 1327/4885 |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | PPARA 2919/4885CA1 2260/4885CA2 4432/4885 |
| US-20060122123-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | PPARA 1983/4885CA1 3835/4885CA2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.